Expression and clinical significance of Ku70, Ku80 and DNA-PKcs proteins in patients with stage I-II non-small cell lung cancer by tissue microarray

Chinese Journal of Lung Cancer

Volumn 10, Issue 3, 2007, Pages 203-205

  Pan, Hong ^a   Zuo, Chuantian ^a   Mao, Naiquan ^a   Chen, Jun ^a   Cao, Ji ^a   Tang, Bujian ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

DNA dependent protein kinase; DNA PK; Immunohistochemistry; Non small cell lung cancer; Tissue microarray

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; DEOXYRIBONUCLEOPROTEIN; KU ANTIGEN; PROTEIN KINASE C; PROTEIN KU80; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 34347372460     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Liu QH, Li LM, Wang JF. Expression and significance of hTERT, P53 and Ki-67 in astrocytoma by tissue microarray. Chin Remedies Clin, 2005, 5(5): 354-356.
2. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 1998, 4(7): 844-847.
3. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol, 2002, 161 (5): 1557-1565.
4. Koike M. Dimerization, translocation and localization of Ku70 and Ku80 proteins. J Radiat Res (Tokyo), 2002, 43(3): 223-236.
5. Martinez JJ, Seveau S, Veiga E, et al. Ku70, a component of DNA-dependent protein kinase, is a mammalian receptor for Rickettsia conorii. Cell, 2005, 123(6): 1013-1023.
6. Ehrenhofer-Murray AE. Chromatin dynamics at DNA replication, transcription and repair. Eur J Biochem, 2004, 271(12): 2335-2349.
7. Chevalier TL, Pignon JP, Bergman B, et al. Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2003, 22: abstr. 6.
8. Keller SM, Adak S, Wagner H, et al. A randomized trial of post-operative adjuvant therapy in patients with completely resected stage II or III A non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med, 2000, 343(17): 1217-1222.